title: Idarubicin in advanced breast cancer: a phase II study.
abstract: Twenty-nine patients with metastatic breast cancer were treated orally with idarubicin (15 mg/m2 X 3 days every 3-4 weeks). Objective response was seen in 31% of all patients. Toxicity was acceptable. There should be further clinical trials of new anthracycline antibiotic.
authors.forename: R
authors.initials: R
authors.lastname: Lionetto
authors.forename: P
authors.initials: P
authors.lastname: Pronzato
authors.forename: P F
authors.initials: PF
authors.lastname: Conte
authors.forename: M R
authors.initials: MR
authors.lastname: Sertoli
authors.forename: D
authors.initials: D
authors.lastname: Amoroso
authors.forename: R
authors.initials: R
authors.lastname: Rosso
mesh_terms: D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003630:Daunorubicin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D015255:Idarubicin; D008875:Middle Aged; D009362:Neoplasm Metastasis
chemical_list: D015255:Idarubicin; D003630:Daunorubicin